Summary
Gaurav Bagwe is a Manager in the Mass Torts Practice. Dr. Bagwe specializes in developing quantitative models for mass tort liability estimation and forecasting. He has extensive experience in economic and statistical modeling, sampling, and data analysis in mass tort cases including bankruptcies, settlement support, and strategic consulting. He has worked on several firm-wide initiatives to incorporate and share knowledge of big data tools as a member and advisor to the Data Science Committee.
Prior to joining Bates White, Dr. Bagwe conducted research in areas of law and economics and political economy. As part of this dissertation, he developed a dynamic game-theoretic model of decision making on the US Supreme Court to measure the justices’ ideologies and adherence to precedent. His other research examines the effect of distance to polling places on voter turnout and the optimal location of polling places.
Education
PhD, Economics, Georgetown University
MA, Economics, Duke University
BS, Economics, Finance, New York University
Selected Work
Selected Experience
- Supported the talc claims valuation expert in advising a corporation about potential liability and expenditure scenarios for talc-related personal injury claims.
- Supported the expert in asbestos liability valuation on behalf of the debtor in In re HONX, Inc., regarding the value of pending and future asbestos-related personal-injury claims.
- In In re Aldrich Pump LLC, et al., supported the expert on behalf of the debtors regarding the value of pending and future asbestos-related personal-injury claims. Leading team in constructing and analyzing complex data sets and developing economic models to estimate the potential liability.
- Supporting the expert in assessing the value of pending and future asbestos-related personal injury claims on behalf of debtors in In re Bestwall LLC. Improving established models to incorporate recent scientific developments.
- Supported advisory opinions and analyses of the expert in resolution of over 80,000 Zantac and generic ranitidine claims brought against GSK.